Arm A: F16IL2 in combination with paclitaxel + Arm B: Paclitaxel
Phase 2Terminated 0 views this week 0 watching💤 Quiet
Interest: 21/100
21
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Merkel Cell Carcinoma
Conditions
Merkel Cell Carcinoma
Trial Timeline
Oct 25, 2013 → Dec 15, 2017
NCT ID
NCT02054884About Arm A: F16IL2 in combination with paclitaxel + Arm B: Paclitaxel
Arm A: F16IL2 in combination with paclitaxel + Arm B: Paclitaxel is a phase 2 stage product being developed by Immatics for Merkel Cell Carcinoma. The current trial status is terminated. This product is registered under clinical trial identifier NCT02054884. Target conditions include Merkel Cell Carcinoma.
What happened to similar drugs?
0 of 1 similar drugs in Merkel Cell Carcinoma were approved
Approved (0) Terminated (0) Active (1)
Hype Score Breakdown
Clinical
12
Activity
0
Company
9
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02054884 | Phase 2 | Terminated |
Competing Products
20 competing products in Merkel Cell Carcinoma